NCT02432716View on ClinicalTrials.gov

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 18, 2018

Study Completion Date

October 18, 2018

Conditions
Down Syndrome
Interventions
DRUG

Insulin glulisine

Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study

DRUG

Saline

Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study

Trial Locations (1)

55130

HealthPartners Neuroscience Center, Saint Paul

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT02432716 - Investigation of the Safety of Intranasal Glulisine in Down Syndrome | Biotech Hunter | Biotech Hunter